| 1 |
34199694 | The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC. | 2021 Jun 4 |
1 |
| 2 |
32770529 | Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review. | 2020 Oct |
1 |
| 3 |
31205516 | The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. | 2019 |
2 |
| 4 |
31675556 | Curcumin functions as a MEK inhibitor to induce a synthetic lethal effect on KRAS mutant colorectal cancer cells receiving targeted drug regorafenib. | 2019 Dec |
3 |
| 5 |
28032528 | Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope? | 2017 Apr |
1 |
| 6 |
28259999 | Clinical and molecular assessment of regorafenib monotherapy. | 2017 Apr |
1 |
| 7 |
26045027 | Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events. | 2015 |
1 |
| 8 |
26161928 | KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer. | 2015 |
5 |
| 9 |
26327919 | Management of regorafenib-related toxicities: a review. | 2015 Sep |
1 |
| 10 |
26489551 | [Long-Term Survival of a Patient with KRAS Mutated Colon Cancer Successfully Treated with Regorafenib]. | 2015 Oct |
1 |
| 11 |
26640390 | Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. | 2015 |
1 |
| 12 |
24623990 | Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management. | 2014 |
1 |
| 13 |
24047557 | [Regorafenib approved in Metastatic Colorectal cancer]. | 2013 Oct |
1 |